QLTI News Alert Qlt Inc (QLTI) 3.72 12/25/2014 02:43:31

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Qlt Inc (QLTI) 3.72 $QLTI

Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)

QLT Announces Results of Annual General Meeting of Shareholders
GlobeNewswire - Tue Dec 16, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" is pleased to announce that, on a vote by ballot, the six incumbent directors of the Company were re-elected at the Company's annual general meeting held on December 15, 2014 (the "Meeting" .
QLTI: 3.72 (+0.08), QLT.TO: 4.26 (+0.02)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

QLT synthetic retinoid comes up short in Phase 2 study
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 6:50AM CST

QLTI: 3.72 (+0.08)

QLT Announces Results From Proof-of-Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) in Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision
GlobeNewswire - Fri Dec 05, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced results from its multi-center, Phase 2a clinical trial of repeated treatments of oral QLT091001 in adult subjects with early age-related macular degeneration (AMD) and impaired dark adaptation and/or impaired low luminance vision. The Company previously announced positive results from its Phase 1b clinical trials for QLT091001 in subjects with the rare inherited retinal degenerative diseases, Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).
QLTI: 3.72 (+0.08), QLT.TO: 4.26 (+0.02)

QLT Announces Departure of Chief Financial Officer
GlobeNewswire - Tue Dec 02, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced that Sukhi Jagpal, Chief Financial Officer of the Company, has notified the Company that he is leaving to pursue other opportunities. Mr. Jagpal will continue in his current role through January 26, 2015. The Company will explore its options to fill the position.
QLTI: 3.72 (+0.08), QLT.TO: 4.26 (+0.02)

Seven Fat Years Of Event-Driven Investing
Chris DeMuth Jr. - at Seeking Alpha - Mon Dec 01, 6:00AM CST

OSHC: 14.25 (-0.14), QLTI: 3.72 (+0.08), VRX: 140.33 (-0.22), GCVRZ: 0.75 (-0.02), COWN: 4.72 (+0.02), YHOO: 50.65 (+0.63), PFN: 10.22 (-0.17), LORL: 79.00 (+0.36), ARCC: 15.86 (+0.07), DTV: 86.82 (-0.05), ABBV: 66.21 (+1.86), GPT: 6.96 (+0.06), STRZA: 29.80 (+0.50), BABA: 105.95 (+0.43)

Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 254.20 (-1.68), QLTI: 3.72 (+0.08), VRX: 140.33 (-0.22), AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), ABT: 45.70 (-0.02), ENDP: 72.10 (+0.34), AKRX: 36.47 (+0.43), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), SLXP: 114.92 (-1.18), MYL: 56.97 (+0.39), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), ICPT: 151.49 (+5.85), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)

Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 254.20 (-1.68), QLTI: 3.72 (+0.08), VRX: 140.33 (-0.22), AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), ABT: 45.70 (-0.02), ENDP: 72.10 (+0.34), AKRX: 36.47 (+0.43), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), SLXP: 114.92 (-1.18), MYL: 56.97 (+0.39), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), ICPT: 151.49 (+5.85), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)

QLT (QLTI) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
QLT (QLTI) Is in Oversold Territory: What’s Next?
QLTI: 3.72 (+0.08)

QLT Looks Undervalued With Significant Upside
Cory Renauer - at Seeking Alpha - Thu Oct 30, 11:40AM CDT

QLTI: 3.72 (+0.08)

QLT (QLTI) Reports Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:00AM CDT
QLT Inc. (QLTI) reported a third-quarter 2014 loss of 10 cents.
QLTI: 3.72 (+0.08), VRX: 140.33 (-0.22), AUXL: 34.40 (+0.18), BMY: 59.15 (-0.01)

QLT beats by $0.02
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:22AM CDT

QLTI: 3.72 (+0.08)

QLT Announces Third Quarter 2014 Results
GlobeNewswire - Tue Oct 28, 6:15AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the third quarter ended September 30, 2014. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP.
QLTI: 3.72 (+0.08), QLT.TO: 4.26 (+0.02)

QLT Appoints Dr. Geoffrey F. Cox as Interim Chief Executive Officer
GlobeNewswire - Fri Oct 24, 6:01AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced that current QLT Board member, Geoffrey F. Cox, Ph.D., has been appointed interim Chief Executive Officer, effective immediately. Dr. Cox brings more than 35 years of business and scientific leadership in the pharmaceutical and biotechnology industries to QLT, 13 years of which have been as Chairman and CEO of public companies. Dr. Cox will continue in his role as a member of the QLT Board of Directors. In conjunction with Dr. Cox's appointment, the QLT Board has disbanded its Executive Transition Committee.
QLTI: 3.72 (+0.08), QLT.TO: 4.26 (+0.02)

Global Glaucoma Treatment Market: Trends and Opportunities 2014-2019
M2 - Wed Oct 15, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h5f725/global_glaucoma) has announced the addition of the "Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)" report to their offering. This report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. The market for glaucoma treatment has grown rapidly in the last decade, based on both increasing number of people with glaucoma and the introduction of new treatments. However, the worldwide glaucoma treatment market is expected to decline that can be attributable to price reduction of drugs due to generic availability of many brands in coming years. The glaucoma pharmaceuticals are segmented into two classes namely prostaglandins analogues (PGAs) and Non PGAs that include beta blockers, carbonic anhydrase inhibitors and alpha agonists. PGAS are the most widely prescribed drug class for glaucoma with latanoprost (brand name Xalatan) the most commonly prescribed drug. Key growth drivers of the market include rising ageing population, healthcare expenditures, medical coverage and new innovative combination drugs. The market players in medication as well as devices segments are totally different and somewhat very fragmented. Leaders in glaucoma medication space include Pfizer Inc, Alcon Inc. (Novartis), Allergan Inc and Merck and Co, Inc. Companies developing glaucoma drug-delivery devices include Ocular Therapeutix Inc, QLT Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC, Euclid Systems Corp and Replenish Inc. In glaucoma laser market, top market leaders include Ellex, Lumenis, Quantel and Lightmed. Key Topics Covered: 1. Executive Summary 2. Glaucoma: A Major Cause of Vision Loss 3. Global Eye Care Market: An Analysis 4. Global Glaucoma Treatment Market: An Analysis 5. Regional Analysis: Glaucoma Treatment Market 6. Market Dynamics: Global Glaucoma Treatment Market 7. Competitive Landscape: Glaucoma Treatment Market 8. Company Profiles: Glaucoma Treatment Market For more information visit http://www.researchandmarkets.com/research/h5...l_glaucoma
AGN: 210.12 (+0.95), QLTI: 3.72 (+0.08), NVS: 93.91 (+0.66)

Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene
PR Newswire - Tue Oct 14, 7:30AM CDT
Today, Analysts Review released its research reports regarding Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Lakeland Industries Inc. (NASDAQ: LAKE), Endo International plc (NASDAQ: ENDP), Actavis plc (NYSE: ACT) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7148-100free.
ENDP: 72.10 (+0.34), ACT: 254.20 (-1.68), QLTI: 3.72 (+0.08), AUXL: 34.40 (+0.18), LAKE: 8.94 (+0.07), CELG: 109.60 (+3.48), CELGZ: 3.34 (-0.01)

Endo to Buy Auxilium for $2.6B, Diversify Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 4:45PM CDT
Endo (ENDP) is set to acquire Auxilium Pharmaceuticals (AUXL) for $2.6 billion in cash as well as stock.
ENDP: 72.10 (+0.34), ACT: 254.20 (-1.68), QLTI: 3.72 (+0.08), AUXL: 34.40 (+0.18)

Market Maker Surveillance Report. FE, PBR, QLTI, CTSO, AGNC, BABA, Highest Net Buy Volume With Lowest Price Friction For Thursday, October 9th 2014
M2 - Fri Oct 10, 4:35AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4573 companies with "abnormal" market making, 961 companies with positive Friction Factors and 4314 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Thursday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Firstenergy Corp (NYSE:FE), Petroleo Brasileiro SA Petrobras (NYSE BR), QLT INC (NASDAQ:QLTI), CytoSorbents Corp (OTC:CTSO), American Capital Agency Corp (NASDAQ:AGNC), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
PBR: 7.60 (-0.11), QLTI: 3.72 (+0.08), FE: 39.74 (+0.73), CTSO: 9.3500 (+0.9900), AGNC: 22.14 (-0.08), BABA: 105.95 (+0.43)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 102

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 124

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 76

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 63

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 72

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading

Top 5 Most Recently Viewed Articles

Seasonal Hiring Booms as Firms Eye Long-Term Talent

Updated Category News Views 327

A Strategic Shift in Seasonal Hiring It ain't just about the holiday rush anymore, folks. Companies are waking up to the idea that seasonal gigs are more than a temporary Band-Aid. This year, nearly 2 out of 5 companies are planning to bring more seasonal folks into the fold compared to last year. That means a good dose of them are looking for longer-term value—like...

Continue Reading
Nebius Secures $700 Million to Accelerate AI Infrastructure Growth

Updated Category News Views 269

Nebius Secures $700 Million to Accelerate AI Infrastructure Growth Nebius Group N.V. (“Nebius Group”, “Nebius” or the “Company”; NASDAQ:NBIS), a prominent player in AI infrastructure, has made an exciting announcement regarding a substantial private placement financing. In a strategic move to bolster its operations, the company has secured USD 700 million from...

Continue Reading
Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO

Updated Category News Views 183

Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a biopharmaceutical company specializing in neuroscience, has made a significant move by appointing Tucker Kelly as the new Chief Financial Officer (CFO). This decision signals the company's commitment to strategic financial management as it gears up for the commercialization of...

Continue Reading
Brookfield Makes Big Moves in Japan's Real Estate Market

Updated Category News Views 302

Brookfield's Bold Ventures into Japan's Real Estate Landscape Canadian investment firm Brookfield Asset Management (TSX: BAM) has recently made headlines with its significant real estate endeavors in Japan, closing two major deals that amount to a staggering $1.6 billion. The Significant Investments Overview The recent acquisitions involve a noteworthy stake in the iconic...

Continue Reading
Pacira BioSciences Facing Legal Challenges and Investor Updates

Updated Category News Views 170

Legal Proceedings Impacting Pacira BioSciences, Inc. Shareholders of Pacira BioSciences, Inc. should be aware of a significant class action lawsuit that is currently unfolding. This lawsuit, noted for its complexity, aims to address allegations of securities fraud impacting investors. The firm representing the investors, is Levi & Korsinsky, a well-established legal group...

Continue Reading